Deal Details
Geron Completes $75 Million Follow-On Offering
Summary
Geron Corporation (“Geron”) (NASDAQ:GERN) recently completed an underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of its common stock, together with accompanying warrants, to purchase 35,714,286 shares of its common stock. The combined offering price to the public of each share of common stock and accompanying warrant was $1.05. The combined offering price to the public of each pre-funded warrant and accompanying warrant was $1.049. The common stock and pre-funded warrants were sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The gross proceeds to Geron from the offering were approximately $75 million, before deducting underwriting discount and estimated offering expenses.
Baird served as an active bookrunner on this offering.
About
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. Geron is currently conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. Geron Corporation is headquartered in Foster City, California.CONTACT US TO LEARN MORE
- Date
- April 2022
- Company
- Geron Corporation
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- North America
Share